Gallbladder imaging on GLP-1 therapy: the label rates, the symptoms that trigger an ultrasound, and why nobody images routinely

The gallbladder is the exception on this site: the test in question is a scan, not a blood draw. It earns a page because gallbladder disease is a named warning on every semaglutide and tirzepatide label, because rapid weight loss from any cause raises the risk of gallstones, and because the label instruction about when to image is short, specific and easy to quote.

The label numbers

Wegovy (section 5.3): treatment is associated with an increased occurrence of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). In the adult weight-reduction trials, cholelithiasis was reported by 1.6% of Wegovy injection-treated patients and 0.7% on placebo, and by 2.5% of Wegovy tablet-treated patients versus 1% on placebo tablets. Cholecystitis was reported by 0.6% of Wegovy injection-treated adults and 0.2% on placebo. The label notes the incidence was higher in treated adolescents than in treated adults.

Zepbound (section 5.4): in the pool of Studies 1 and 2, cholelithiasis was reported in 1.1% of Zepbound-treated patients and 1% on placebo, cholecystitis in 0.7% versus 0.2%, and cholecystectomy (gallbladder removal) in 0.2% versus none.

Mounjaro: acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of Mounjaro-treated patients and 0% on placebo.

These are absolute numbers over trial durations of a year or more. Read them as: uncommon, more common than placebo, and worth knowing the symptoms of.

The instruction

Every label says the same thing in almost the same words: if cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated. Zepbound's short version adds cholecystitis. What none of them says is to image before therapy, at intervals, or in the absence of symptoms. The instruction is conditional on suspicion, and suspicion comes from symptoms.

Why weight loss itself is part of the story

Gallstones form when bile becomes supersaturated with cholesterol and the gallbladder empties poorly. Rapid weight loss from any cause (very low calorie diets, bariatric surgery) is a well-known trigger for both. GLP-1 receptor agonists also slow gallbladder emptying directly. The label rates therefore reflect two things at once, the drug and the weight loss it produces, and the label does not try to separate them.

What "suspected" looks like

MedlinePlus describes the symptoms of gallstones: pain in the upper right or middle abdomen that can be constant, cramping or sharp, may spread to the back or below the right shoulder blade, and often follows a fatty meal. Cholecystitis adds fever, and a stone in the bile duct adds yellowing of the skin and eyes, dark urine and pale stools. Nausea is common but is also the commonest GLP-1 side effect, so nausea alone is not the trigger; pain is.

What is done when it is suspected

Gallbladder studies means, in the first instance, an abdominal ultrasound. MedlinePlus lists it as the usual test for gallstones. It shows stones, a thickened gallbladder wall, fluid around the gallbladder and whether the common bile duct is dilated. It is fasting, painless and radiation-free.

Blood tests alongside: the liver enzymes (a stone in the duct raises alkaline phosphatase and bilirubin, often ALT too), lipase (gallstones are a leading cause of pancreatitis, and the two warnings overlap), and a CBC for the white cell count in cholecystitis.

Follow-up: depends on what is found. Stones without inflammation may be watched. Cholecystitis or a duct stone is a surgical or endoscopic problem. The labels leave the decision about continuing therapy after a gallbladder event to the clinician.

How often

• Routine imaging: never, in the labels.
• Trigger: the pain pattern above, with or without fever or jaundice. Same-day contact with your prescriber; same-day emergency care if there is fever, jaundice or pain you cannot manage.
• After a gallbladder event: the follow-up your surgeon or gastroenterologist sets.

What to discuss with your prescriber

• Any past gallstone attacks or gallbladder surgery. If your gallbladder has been removed, stones in the gallbladder are no longer possible but duct stones still are.
• What pain pattern should prompt a call, in plain terms, so you do not dismiss it as ordinary GLP-1 nausea.
• Whether faster escalation or a higher dose changes anything for you, given the rate of weight loss is part of the risk.

For the dose-by-dose adverse reaction tables, see the Semaglutide Hub and Tirzepatide Hub. The rates above come from brand trials; compounded semaglutide and tirzepatide, including products FormBlends dispenses, are not FDA approved and were not studied in those trials.